Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

192 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Validation of two global impression questionnaires for incontinence.
Yalcin I, Bump RC. Yalcin I, et al. Am J Obstet Gynecol. 2003 Jul;189(1):98-101. doi: 10.1067/mob.2003.379. Am J Obstet Gynecol. 2003. PMID: 12861145 Clinical Trial.
A retrospective pooled analysis of duloxetine safety in 23,983 subjects.
Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L. Gahimer J, et al. Among authors: yalcin i. Curr Med Res Opin. 2007 Jan;23(1):175-84. doi: 10.1185/030079906X162719. Curr Med Res Opin. 2007. PMID: 17257478
Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence.
Castro-Diaz D, Palma PC, Bouchard C, Haab F, Hampel C, Carone R, Zepeda Contreras S, Rodriguez Ginorio H, Voss S, Yalcin I, Bump RC; Duloxetine Dose Escalation Study Group. Castro-Diaz D, et al. Among authors: yalcin i. Int Urogynecol J Pelvic Floor Dysfunct. 2007 Aug;18(8):919-29. doi: 10.1007/s00192-006-0256-x. Epub 2006 Dec 12. Int Urogynecol J Pelvic Floor Dysfunct. 2007. PMID: 17160693 Clinical Trial.
Safety and adverse event profile of duloxetine.
Wernicke JF, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L. Wernicke JF, et al. Among authors: yalcin i. Expert Opin Drug Saf. 2005 Nov;4(6):987-93. doi: 10.1517/14740338.4.6.987. Expert Opin Drug Saf. 2005. PMID: 16255658 Review.
The studied dose range is up to 400 mg/day (administered 200 mg b.i.d) but the maximum dose approved for marketing is 120 mg/day (administered 60 mg b.i.d). ...
The studied dose range is up to 400 mg/day (administered 200 mg b.i.d) but the maximum dose approved for marketing is 120 mg/day (adm …
Minimal clinically important differences in Incontinence Quality-of-Life scores in stress urinary incontinence.
Yalcin I, Patrick DL, Summers K, Kinchen K, Bump RC. Yalcin I, et al. Urology. 2006 Jun;67(6):1304-8. doi: 10.1016/j.urology.2005.12.006. Urology. 2006. PMID: 16750246 Clinical Trial.
Real-time urinary diaries were completed, along with the I-QOL and PGI-I. RESULTS: The within-treatment and between-treatment MCID for the I-QOL total score was 6.3 and 2.5, respectively. ...Duloxetine 80 mg significantly improved the I-QOL total and s …
Real-time urinary diaries were completed, along with the I-QOL and PGI-I. RESULTS: The within-treatment and between-treatment …
Reductions in stress urinary incontinence episodes: what is clinically important for women?
Yalcin I, Peng G, Viktrup L, Bump RC. Yalcin I, et al. Neurourol Urodyn. 2010 Mar;29(3):344-7. doi: 10.1002/nau.20744. Neurourol Urodyn. 2010. PMID: 19475576 Clinical Trial.
METHODS: We used an integrated database that included data from 1,913 women with SUI who were enrolled in four randomized, placebo-controlled pharmaceutical clinical trials and examined the relationship between various levels of reduction in IEF and minimally clinical important d …
METHODS: We used an integrated database that included data from 1,913 women with SUI who were enrolled in four randomized, placebo-controlle …
Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence.
Bent AE, Gousse AE, Hendrix SL, Klutke CG, Monga AK, Yuen CK, Muram D, Yalcin I, Bump RC. Bent AE, et al. Among authors: yalcin i. Neurourol Urodyn. 2008;27(3):212-21. doi: 10.1002/nau.20471. Neurourol Urodyn. 2008. PMID: 17580357 Clinical Trial.
Secondary outcome measures included the Incontinence Quality of Life (I-QOL) scores, the ICI Quality of Life (ICIQ-SF) score, and the Patient Global Impression of Improvement (PGI-I) rating. ...Significant benefits were also demonstrated with duloxetine for improvem …
Secondary outcome measures included the Incontinence Quality of Life (I-QOL) scores, the ICI Quality of Life (ICIQ-SF) score, and the …
Comparison of physician and patient assessments of incontinence severity and improvement.
Yalcin I, Viktrup L. Yalcin I, et al. Int Urogynecol J Pelvic Floor Dysfunct. 2007 Nov;18(11):1291-5. doi: 10.1007/s00192-007-0326-8. Epub 2007 Feb 28. Int Urogynecol J Pelvic Floor Dysfunct. 2007. PMID: 17333436
Compare the subjective and objective assessment of stress urinary incontinence (SUI) severity and improvement with treatment using patient- and clinician-rated global impression of severity (PGI-S, CGI-S) and improvement (PGI-I, CGI-I) scales. ...PGI-S and CGI-S (no …
Compare the subjective and objective assessment of stress urinary incontinence (SUI) severity and improvement with treatment using patient- …
Duloxetine treatment of stress urinary incontinence in women: effects of demographics, obesity, chronic lung disease, hypoestrogenism, diabetes mellitus, and depression on efficacy.
Viktrup L, Yalcin I. Viktrup L, et al. Among authors: yalcin i. Eur J Obstet Gynecol Reprod Biol. 2007 Jul;133(1):105-13. doi: 10.1016/j.ejogrb.2006.05.003. Eur J Obstet Gynecol Reprod Biol. 2007. PMID: 16769171
Efficacy outcome variables included a weekly incontinence episodes frequency (IEF) from patient-completed diaries, the Incontinence Quality-of-Life (I-QOL) questionnaire score, and a Patient Global Impression of Improvement rating. ...There was a significantly different …
Efficacy outcome variables included a weekly incontinence episodes frequency (IEF) from patient-completed diaries, the Incontinence Quality- …
Validation of a two-item quantitative questionnaire for the triage of women with urinary incontinence.
Bent AE, Gousse AE, Hendrix SL, Klutke CG, Monga AK, Yuen CK, Meadows ES, Yalcin I, Muram D; Duloxetine Mixed Urinary Incontinence Study Group. Bent AE, et al. Among authors: yalcin i. Obstet Gynecol. 2005 Oct;106(4):767-73. doi: 10.1097/01.AOG.0000178168.33249.49. Obstet Gynecol. 2005. PMID: 16199634
192 results
Jump to page
Feedback